Third Quarter 2023 Operating & Financial Results Conference Call / Webinar November 8th, 2023 4:30 PM Eastern Time ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Nu ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Margave – Chief Financial Officer Conference Call Participants Nicole Leber Good afternoon, everyone. I’m Nicole Leber with Investor Relations here at Lantern Pharma. Welcome to our Second Quarter 2023 Earnings Call. I will be your host for today’s call. As a reminder, this call is being recorded and all attendees are ...

Second Quarter 2023 Operating & Financial Results Conference Call / Webinar August 9th, 2023 4:30 PM Eastern Time NASDAQ: LTRN r m a Forward Looking Statements 1 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Officer and Secretary Conference Call Participants Michael King - EF Hutton Nicole Leber Good afternoon, everyone. I'm Nicole Weber with Investor Relations here at Lantern Pharma. Welcome to our First Quarter 2023 Earnings Call. I will be your host for today's call. As a ...

Lantern Pharma Inc. Corporate Overview May 10th, 2023 | --- | --- | |--------------|---------------------------------------------------------------------------------------------------------------------------------------| | | | | | Leveraging A.I., machine learning & genomics to transform the cost, pace, and timeline of oncology drug discovery and development | | NASDAQ :LTRN | | Forward Looking Statements 1 This presentation contains forward-looking statements within the meaning of Section 27A of the Securi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39318 46-3973463 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2022 Results Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Officer and Secretary Kishor Bhatia - Chief Scientific Officer Conference Call Participants John Vandermosten - Zacks Research Michael King - EF Hutton Nicole Leber Welcome to our fourth quarter and full-year 2022 earnings call. I will be your host for today's ...

Fourth Quarter 2022 Operating & Financial Results Conference Call / Webinar March 20th, 2023 4:30 PM Eastern Time NASDAQ :LTRN Forward Looking Statements 1 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advant ...